BRPI0409663A - método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento - Google Patents

método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento

Info

Publication number
BRPI0409663A
BRPI0409663A BRPI0409663A BRPI0409663A BR PI0409663 A BRPI0409663 A BR PI0409663A BR PI0409663 A BRPI0409663 A BR PI0409663A BR PI0409663 A BRPI0409663 A BR PI0409663A
Authority
BR
Brazil
Prior art keywords
systemic delivery
growth
bioactive compounds
lipid
derived bioactive
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Kester
Thomas Stover
Tao Lowe
James Adair
Young Shin Kim
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of BRPI0409663A publication Critical patent/BRPI0409663A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783—Organic host/matrix, e.g. lipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO E SISTEMA PARA O ENVIO SISTêMICO DE COMPOSTOS BIOATIVOS DERIVADOS DE LIPìDEO DE DETENçãO DE CRESCIMENTO". Sistema e método para a otimização do envio sistêmico de drogas bioativas derivadas de lipídeo de detenção de crescimento ou agentes de terapia de gene a um animal ou ser humano em necessidade dos referidos agentes, utilizando sistemas de montagem de nano escala, tais como lipossomas, dispersões de nano partículas re-absorvíveis e de não agregação, nano partículas de metal ou semicondutoras, ou materiais poliméricos tais como dendrímeros ou hidrogéis, cada um dos quais exibe aprimorada solubilidade de lipídeo, permeabilidade celular, e maior meia vida de circulação e perfil farmacocinético com alvo tumoral ou vascular.
BRPI0409663 2003-04-25 2004-04-26 método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento BRPI0409663A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46593803P 2003-04-25 2003-04-25
PCT/US2004/012783 WO2004096140A2 (en) 2003-04-25 2004-04-26 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds

Publications (1)

Publication Number Publication Date
BRPI0409663A true BRPI0409663A (pt) 2006-04-18

Family

ID=33418310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409663 BRPI0409663A (pt) 2003-04-25 2004-04-26 método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento

Country Status (9)

Country Link
US (2) US9028863B2 (pt)
EP (1) EP1617808A4 (pt)
JP (2) JP5107573B2 (pt)
KR (1) KR20060015534A (pt)
CN (1) CN1812766A (pt)
AU (1) AU2004233873B2 (pt)
BR (1) BRPI0409663A (pt)
CA (1) CA2523413A1 (pt)
WO (1) WO2004096140A2 (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369938B1 (en) 1996-05-28 2002-04-09 Fujitsu Limited Multi-wavelength light amplifier
US6603596B2 (en) 1998-03-19 2003-08-05 Fujitsu Limited Gain and signal level adjustments of cascaded optical amplifiers
US7968529B2 (en) 2003-01-20 2011-06-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
WO2004096140A2 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
ES2562778T3 (es) * 2003-12-02 2016-03-08 The Ohio State University Research Foundation Ácidos grasos de cadena corta unidos a motivos quelantes de Zn2+ como una clase novedosa de inhibidores de histona deacetilasa
EP1773936B1 (en) * 2004-06-01 2015-09-02 The Penn State Research Foundation Unagglomerated core/shell nanocomposite particles
US7316816B2 (en) * 2004-06-10 2008-01-08 Agency For Science Technology And Research Temperature and pH sensitive copolymers
EP1618876A1 (en) * 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for prevention and treatment of atherosclerosis
DE102004039875A1 (de) * 2004-08-17 2006-03-09 Universität Dortmund Nanotransportsystem mit dendritischer Architektur
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP1813288B1 (en) * 2004-11-18 2018-07-18 Terumo Kabushiki Kaisha Medicinal composition, medicinal preparation, and combination preparation
AU2005310341A1 (en) 2004-11-30 2006-06-08 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
EP1868571A4 (en) * 2005-03-02 2011-10-26 Univ Northeastern MITOCHONDRIOTROPIC PHOSPHOLIPIDE VESICLES
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
WO2006116065A1 (en) * 2005-04-21 2006-11-02 The Trustees Of Boston College Methods for molecular delivery into cells using nanotube spearing
US20060257493A1 (en) * 2005-04-28 2006-11-16 Amiji Mansoor M Nanoparticulate delivery systems for treating multi-drug resistance
JP4791082B2 (ja) * 2005-05-30 2011-10-12 株式会社クラレ リポソームおよびそれを含む皮膚外用剤
JP4931369B2 (ja) * 2005-05-31 2012-05-16 ポーラ化成工業株式会社 リポソームおよびそれを含む処置用の組成物
GR1005807B (el) * 2005-07-13 2008-02-06 Αρισταρχος Παπαγιανναρος Ρυθμιστικο λιποσωμιακο συστημα ελεγχομενης αποδεσμευσης: νεα φαρμακοτεχνικη μορφη για εγκλωβισμο αντικαρκινικων φαρμακων με βαση την τεχνολογια των λιποσωματων και των δενδριμερων
JP5815915B2 (ja) * 2005-10-11 2015-11-17 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム
US7754483B2 (en) * 2005-11-09 2010-07-13 The Penn State Research Foundation Systems and methods for selection and maintenance of homogeneous and pluripotent human embryonic stem cells
KR100745744B1 (ko) * 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
BRPI0619938A2 (pt) 2005-12-16 2011-10-25 Univ Kansas nano agrupamentos para envio de terapêuticos
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP2010501039A (ja) * 2006-08-17 2010-01-14 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション デンドリマー並びにその製造及び使用方法
WO2008036700A2 (en) * 2006-09-19 2008-03-27 3M Innovative Properties Company Templated metal oxide particles and methods of making
EP2091517B1 (en) 2006-11-16 2013-05-29 The University of Akron Materials and methods of introducing genetic material into living cells
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US20080294089A1 (en) * 2007-06-06 2008-11-27 Biovaluation & Analysis, Inc. Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
WO2009126442A1 (en) * 2008-04-10 2009-10-15 Board Of Regents, The University Of Texas System Compositions and methods for composite nanoparticle hydrogels
JP5658141B2 (ja) * 2008-05-08 2015-01-21 スリーエム イノベイティブ プロパティズ カンパニー ナノ粒子の製造方法
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
EP2440181A2 (en) * 2009-06-08 2012-04-18 Epitarget AS Acoustically sensitive drug delivery particles comprising phosphatidylethanolamine
GB0910723D0 (en) * 2009-06-22 2009-08-05 Sylentis Sau Novel drugs for inhibition of gene expression
ES2351756B1 (es) 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
US9063138B2 (en) * 2009-10-15 2015-06-23 Robert Bosch Gmbh Device and method for indirect electronic condition control in biomolecule detection platforms
US9149544B2 (en) * 2009-11-06 2015-10-06 The Penn State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
IT1396436B1 (it) * 2009-11-16 2012-11-23 Icf Srl Composizione per la prevenzione ed il trattamento delle patologie odontostomatologiche degli animali e relativi usi.
US20110301456A1 (en) * 2010-06-07 2011-12-08 Malignext Targeting Technologies, Inc. Tissue Marking for Lesion Removal
CA2808313C (en) 2010-08-13 2021-04-13 Rhode Island Board Of Governors For Higher Education Liposomes comprising ph low insertion peptide (phlip) polypeptides
US20140314664A1 (en) * 2011-01-09 2014-10-23 Anp Technologies, Inc. Hydrophobic Molecule-Induced Branched Polymer Aggregates And Their Use
WO2012125486A1 (en) 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
CA2848173C (en) 2011-05-10 2019-07-02 The Penn State Research Foundation Ceramide anionic liposome compositions
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
US9717695B2 (en) 2012-05-18 2017-08-01 Georgia State University Research Foundation, Inc. Constructs for diagnosing and treating inflammatory bowel diseases and colon cancer
CN103113516B (zh) * 2013-02-01 2015-06-03 厦门大学 温度敏感型有机/无机杂化嵌段共聚物及制备方法与用途
WO2014144421A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Ceramide reversal of multi-drug resistance
EP3046547A4 (en) * 2013-09-18 2017-05-24 Stc.Unm Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo
KR101376135B1 (ko) * 2013-10-29 2014-03-19 (주) 화천 활성성분이 함유된 리포좀을 하이드로젤 입자에 물리적으로 포접하는 방법 및 이를 함유하는 화장료 조성물
CN105814155A (zh) 2013-12-09 2016-07-27 3M创新有限公司 可固化倍半硅氧烷聚合物、组合物、制品和方法
US9851358B2 (en) 2014-01-08 2017-12-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination
WO2015108134A1 (ja) * 2014-01-17 2015-07-23 株式会社西崎創薬研究所 Ｇｌｕｔ４エンドサイトーシス抑制剤
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015195355A1 (en) 2014-06-20 2015-12-23 3M Innovative Properties Company Adhesive compositions comprising a silsesquioxane polymer crosslinker, articles and methods
US10370564B2 (en) 2014-06-20 2019-08-06 3M Innovative Properties Company Adhesive compositions comprising a silsesquioxane polymer crosslinker, articles and methods
US9957416B2 (en) 2014-09-22 2018-05-01 3M Innovative Properties Company Curable end-capped silsesquioxane polymer comprising reactive groups
KR20170063735A (ko) 2014-09-22 2017-06-08 쓰리엠 이노베이티브 프로퍼티즈 캄파니 실세스퀴옥산 중합체 코어와 실세스퀴옥산 중합체 외층, 및 반응성 기를 포함하는 경화성 중합체
AU2016291224B2 (en) * 2015-07-09 2021-12-23 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
BR112018067927A2 (pt) * 2016-03-09 2019-01-02 Technion Res & Development Found Ltd formulação, método de tratamento de plantas, método agrícola e kit
DE102016119102A1 (de) * 2016-10-07 2018-04-12 Forschungszentrum Jülich GmbH Translokation von synthetischen Polymeren durch Lipidmembrane
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
JP7252132B2 (ja) * 2017-03-29 2023-04-04 インスティテュート オブ ベーシック メディカル サイエンシズ チャイニーズ アカデミー オブ メディカル サイエンシズ 核酸送達試薬の調製における化合物または伝統的漢方薬抽出物の応用およびその関連生成物
RU2019139516A (ru) * 2017-05-30 2021-06-30 Эллюм Лимитед Aгрегаты наночастиц
CN107815470B (zh) * 2017-10-11 2021-03-23 江苏大学 一种脂质体/凝胶复合型基因活化支架的制备方法
US11202860B2 (en) * 2018-06-06 2021-12-21 International Business Machines Corporation Controlled drug delivery in point-of-care drug delivery system based on real-time monitoring with integrated sensor
JP2022510170A (ja) * 2018-11-26 2022-01-26 アリサ バイオサイエンシーズ エルエルシー 細胞膜を含有するナノ粒子およびその使用
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
WO2021101340A1 (ko) * 2019-11-22 2021-05-27 차의과학대학교 산학협력단 리포좀 조성물을 포함하는 항암 치료 보조용 조성물 및 이를 이용한 약물 전달 방법

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4898735A (en) 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
US4797285A (en) 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4812314A (en) 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US6312679B1 (en) * 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US5043166A (en) 1987-01-09 1991-08-27 Hadasit Medical Research, Inc. Liposome/anthraquinone drug composition and method
NO870299L (no) 1987-01-23 1988-07-25 Yissum Research And Dev Comp O Liposom/antrakinon-legemiddelpreparat og fremgangsmaate for dets fremstilling.
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5401413A (en) 1991-02-11 1995-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for enhancing the biodegradation of biodegradable organic wastes
US5244574A (en) 1991-02-11 1993-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for treating oil spills on water
US5593508A (en) 1991-02-11 1997-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Moist, absorbent material for cleaning articles and surfaces
DE9301068U1 (de) * 1993-01-27 1994-05-26 Goldwell Ag Kosmetisches Mittel
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
EP0713387B1 (en) 1993-08-06 1998-03-04 Opperbas Holding B.V. A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
CA2168671C (en) 1993-08-06 2007-04-10 Yechezkel Barenholz A method for high loading of vesicles with biopolymeric substances
AU691886B2 (en) * 1994-02-02 1998-05-28 Transave, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
US6235308B1 (en) 1994-06-10 2001-05-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating hypertension
EP0767655B1 (en) 1994-06-10 2004-08-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of treating hypertension
US5622715A (en) 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US6066331A (en) 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US5591453A (en) 1994-07-27 1997-01-07 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
WO1997007785A1 (en) 1995-08-31 1997-03-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipidic vesicles: methods of use and compositions
US5948756A (en) 1995-08-31 1999-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipoprotein compositions
US5741514A (en) 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
AU2284697A (en) * 1996-04-11 1997-10-29 University Of British Columbia, The Fusogenic liposomes
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
WO1997049387A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
US6832735B2 (en) * 2002-01-03 2004-12-21 Nanoproducts Corporation Post-processed nanoscale powders and method for such post-processing
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
JP4656675B2 (ja) * 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
US5810873A (en) * 1997-07-15 1998-09-22 Advanced Cardiovascular Systems, Inc. Stent crimping tool and method of use
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) * 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
US6734171B1 (en) * 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
AU1350099A (en) 1997-12-01 1999-06-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulations for topical treatment of skin infections
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
IL136343A0 (en) 1997-12-04 2001-05-20 Yissum Res Dev Co Combined chemo-immunotherapy with liposomal drugs and cytokines
DE69836151T2 (de) 1998-01-29 2007-02-01 Millenium Biologix Inc., Kingston Synthetisches biomaterial
US7029680B1 (en) 1998-02-03 2006-04-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Delivery of immunogenic molecules vis HBsAg particles
DE69926342T2 (de) 1998-02-03 2006-01-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln
AU757686B2 (en) 1998-03-31 2003-03-06 New York University Liposomal bupivacaine compositions and methods of preparation
AU754559B2 (en) 1998-08-12 2002-11-21 New York University Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
GR1003359B (el) 1998-12-24 2000-04-10 �.�. ����������� �.�.�.�. Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου
KR20010101837A (ko) 1999-02-08 2001-11-14 스톤 스티븐 에프. 리포좀 크기 조절 방법
AU780828B2 (en) 1999-06-15 2005-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Enzymatic preparation of phospholipids in aqueous media
US6924130B1 (en) 1999-06-15 2005-08-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Enzymatic transesterification or hydrolysis of phospholipids in aqueous media
CA2393595A1 (en) * 1999-12-10 2001-06-14 Gigi Chiu Lipid carrier compositions with protected surface reactive functions
EP1274399B1 (en) 2000-01-28 2005-04-13 Alza Corporation Liposomes containing an entrapped compound in supersaturated solution
US7056653B2 (en) 2000-02-10 2006-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Detection of binding of charged species using PH- or potential-sensitive probes
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
JP2004518707A (ja) 2001-02-13 2004-06-24 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム カロテノイドを充填されたリポソーム
IL159334A0 (en) 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
WO2003000232A2 (en) 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
ES2339228T3 (es) 2001-08-23 2010-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Complejos de platino y sus usos en terapia.
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
EP1429726A2 (en) 2001-09-06 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
US20040219201A1 (en) 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
AU2004218489A1 (en) 2003-02-28 2004-09-16 Alza Corporation Liposome composition for reduction of liposome-induced complement activation
US20060198882A1 (en) 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US8545830B2 (en) * 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
WO2004096140A2 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
JP4695075B2 (ja) 2003-06-18 2011-06-08 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム トランスフェクションで使用するためのスフィンゴ脂質ポリアルキルアミン抱合体
WO2005041932A2 (en) 2003-11-03 2005-05-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
JP2008512444A (ja) 2004-09-09 2008-04-24 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 神経変性状態の治療のための、両親媒性弱塩基様テンパミンを含むリポソーム製剤
EP1793804A2 (en) 2004-09-09 2007-06-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of liposomal glucocorticoids for treating inflammatory states
AU2005295072A1 (en) 2004-10-08 2006-04-20 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
JP2008520560A (ja) 2004-11-15 2008-06-19 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 組合せ治療
JPWO2007004300A1 (ja) 2005-07-06 2009-01-22 株式会社ドクターシーラボ 化粧品
CA2627657A1 (en) 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusal Em A method for preparing liposomes and uses thereof
WO2007049279A2 (en) 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A liposomal combination and uses thereof
WO2007066335A2 (en) 2005-12-08 2007-06-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods for affecting liposome composition by ultrasound irradiation
JP5660561B2 (ja) 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド ジョイント部の潤滑に関するグリセロリン脂質の使用
US20110092768A1 (en) 2007-10-31 2011-04-21 Given Imaging Ltd. Device, system and method for in-vivo analysis
US9078812B2 (en) 2007-12-06 2015-07-14 The Bay Zoltan Foundation For Applied Research Particulate drug carriers as desensitizing agents
EP2252266A1 (en) 2008-02-11 2010-11-24 Yissum Research Development Company of the Hebrew University of Jerusalem Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
EP2339951A1 (en) 2008-07-10 2011-07-06 Given Imaging Ltd. Device, method and kit for in vivo detection of a biomarker
KR20120081938A (ko) 2008-10-07 2012-07-20 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 스핑고마이엘린을 포함하는 리포좀 시스템
WO2011092708A2 (en) 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation

Also Published As

Publication number Publication date
JP2006524707A (ja) 2006-11-02
CA2523413A1 (en) 2004-11-11
EP1617808A4 (en) 2011-11-02
JP2011063615A (ja) 2011-03-31
CN1812766A (zh) 2006-08-02
KR20060015534A (ko) 2006-02-17
US9028863B2 (en) 2015-05-12
AU2004233873A1 (en) 2004-11-11
US20130295159A1 (en) 2013-11-07
WO2004096140A3 (en) 2005-03-31
JP5107573B2 (ja) 2012-12-26
WO2004096140A2 (en) 2004-11-11
US20050025820A1 (en) 2005-02-03
US9326953B2 (en) 2016-05-03
AU2004233873B2 (en) 2010-11-18
JP5888849B2 (ja) 2016-03-22
EP1617808A2 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
BRPI0409663A (pt) método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento
Li et al. Tailoring materials for modulation of macrophage fate
Liu et al. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer
Huang et al. Preparation and drug delivery of dextran-drug complex
Foox et al. Drug delivery from gelatin-based systems
Gu et al. Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration
Song et al. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs
US20190023743A1 (en) Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
Tautzenberger et al. Nanoparticles and their potential for application in bone
Fenske et al. Liposomal nanomedicines
Tan et al. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo
US20150044279A1 (en) Methods and compositions for enhancing immune response
Chen et al. Study of magnetic silk fibroin nanoparticles for massage-like transdermal drug delivery
CN106793970A (zh) 用于诊断及治疗的纳米载剂及其加工
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
KR102264820B1 (ko) 지질과 리포좀의 안정된 제제
Chan et al. Review on Medusa®: a polymer-based sustained release technology for protein and peptide drugs
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
Jin et al. Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery
Dow Liposome–nucleic acid immunotherapeutics
ATE438385T1 (de) Pharmazeutische zusammensetzung
Modaresi et al. Preparation and characterization of self-assembled chitosan nanoparticles for the sustained delivery of streptokinase: an in vivo study
Lanier et al. Magnetically triggered release of biologics
Sadozai et al. Recent developments in liposome‐based veterinary therapeutics
Feng et al. Cancer cell–membrane biomimetic boron nitride nanospheres for targeted cancer therapy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.